PRA Health Sciences, Inc. (NASDAQ:PRAH) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share guidance of $3.11-$3.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.15. The company issued revenue guidance of $1.825-$1.855 billion, compared to the consensus revenue estimate of $1.82 billion.

Shares of PRA Health Sciences, Inc. (NASDAQ PRAH) traded up 0.20% during trading on Monday, hitting $74.23. 694,032 shares of the stock were exchanged. PRA Health Sciences, Inc. has a 12-month low of $46.52 and a 12-month high of $79.98. The stock has a 50-day moving average of $75.01 and a 200 day moving average of $66.37. The stock has a market cap of $4.64 billion, a P/E ratio of 44.34 and a beta of 0.45.

A number of equities research analysts recently weighed in on the stock. Bank of America Corporation assumed coverage on shares of PRA Health Sciences in a research note on Monday, June 26th. They set a buy rating and a $89.00 price objective on the stock. BidaskClub cut shares of PRA Health Sciences from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Citigroup Inc. restated a buy rating and set a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Credit Suisse Group restated an outperform rating and set a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC set a $73.00 price objective on shares of PRA Health Sciences and gave the company a buy rating in a research note on Thursday, June 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $73.00.

TRADEMARK VIOLATION NOTICE: “PRA Health Sciences, Inc. (NASDAQ:PRAH) Updates FY17 Earnings Guidance” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/pra-health-sciences-inc-nasdaqprah-updates-fy17-earnings-guidance.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.